Evidence map›Paper›PMID 26348139›Full record

ArticleToxicology and applied pharmacology2015

A fetal whole ovarian culture model for the evaluation of CrVI-induced developmental toxicity during germ cell nest breakdown.

Jone A Stanley, Joe A Arosh, Robert C Burghardt, Sakhila K Banu

Abstract read
In one paragraph

Article in Toxicology and applied pharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. The correlation between exposure to BPA and the decrease of the ovarian reserve.International journal of clinical and experimental pathology · 2018
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Jone A StanleyDepartment of Veterinary Integrative Biosciences, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, TX 77843, USA.
Joe A AroshDepartment of Veterinary Integrative Biosciences, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, TX 77843, USA.
Robert C BurghardtDepartment of Veterinary Integrative Biosciences, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, TX 77843, USA.
Sakhila K BanuDepartment of Veterinary Integrative Biosciences, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, TX 77843, USA. Electronic address: skbanu@cvm.tamu.edu.
Texas A&M University · US

Funding

TARGETED GENOMICS FACILITY COREP30ES023512 · NIEHS · TEXAS A&M AGRILIFE RESEARCH · PI THREADGILL, DAVID W. · 2014 to 2017
$3.3M
Mechanism of Prenatal Chromium-VI Exposure and Germ Cell Apoptosis in the OvaryR01ES025234 · NIEHS · TEXAS A&M AGRILIFE RESEARCH · PI BANU, SAKHILA · 2016 to 2020
$1.7M
ACQUISITION OF A CONFOCAL/MULTIPHOTON MICROSCOPY SYSTEMS10RR022532 · NCRR · TEXAS A&M UNIVERSITY · PI BURGHARDT, ROBERT C · 2006 to 2006
$499k
Chromium VI-induced toxicity on Female Reproductive FunctionR21ES020561 · NIEHS · TEXAS A&M UNIVERSITY · PI BANU, SAKHILA · 2011 to 2012
$403k
NCRR NIH HHS 1 S10 RR22532-01NCRR NIH HHS S10 RR022532NIEHS NIH HHS ES020561-01NIEHS NIH HHS P30 ES023512NIEHS NIH HHS P30ES023512NIEHS NIH HHS R01 ES025234NIEHS NIH HHS R21 ES020561
6 · The paper itself

Abstract

Prenatal exposure to endocrine disrupting chemicals (EDCs), including bisphenol A, dioxin, pesticides, and cigarette smoke, has been linked to several ovarian diseases such as premature ovarian failure (POF) and early menopause in women. Hexavalent chromium (CrVI), one of the more toxic heavy metals, is widely used in more than 50 industries. As one of the world's leading producers of Cr compounds, the U.S. is facing growing challenges in protecting human health against adverse effects of CrVI. Our recent findings demonstrated that in vivo CrVI exposure during gestational period caused POF in F1 offspring. Our current research focus is three-fold: (i) to identify the effect of CrVI on critical windows of great vulnerability of fetal ovarian development; (ii) to understand the molecular mechanism of CrVI-induced POF; (iii) to identify potential intervention strategies to mitigate or inhibit CrVI effects. In order to accomplish these goals we used a fetal whole ovarian culture system. Fetuses were removed from the normal pregnant rats on gestational day 13.5. Fetal ovaries were cultured in vitro for 12 days, and treated with or without 0.1 ppm potassium dichromate (CrVI) from culture day 2-8, which recapitulated embryonic day 14.5-20.5, in vivo. Results showed that CrVI increased germ cell/oocyte apoptosis by increasing caspase 3, BAX, p53 and PUMA; decreasing BCL2, BMP15, GDF9 and cKIT; and altering cell cycle regulatory genes and proteins. This model system may serve as a potential tool for high throughput testing of various drugs and/or EDCs in particular to assess developmental toxicity of the ovary.

Indexed as

AnimalsApoptosisApoptosis Regulatory Proteinsbcl-2-Associated X ProteinBone Morphogenetic Protein 15Caspase 3ChromiumDose-Response Relationship, DrugFemaleFetusGerm CellsGrowth Differentiation Factor 9OocytesOrgan Culture TechniquesOvaryPotassium DichromateApoptosis Regulatory ProteinsBax protein, ratBbc3 protein, ratbcl-2-Associated X ProteinBmp15 protein, ratBone Morphogenetic Protein 15Casp3 protein, ratCaspase 3ChromiumGdf9 protein, ratGrowth Differentiation Factor 9Potassium DichromateTumor Suppressor Protein p53ApoptosisChromiumFetal ovaryGerm cell

Identifiers

PMID26348139
PMCPMC4628871
OpenAlexW1592023792

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.